Study on the mechanism of PD1/PD-L1 inhibitors based on TR-FRET technology

As immune checkpoint inhibitors targeting the same pathway, PD1 inhibitors and PD-L1 inhibitors enhance T cell recognition and killing of tumor cells by blocking the binding between PD1 and PD-L1. Although they act on the same pathway, their mechanisms differ. PD-L1 inhibitors are IgG1 antibodies, which have the biological function of recognizing pathogenic antigens and can identify PD-L1 expressed on tumor cell surfaces. PD-L1 inhibitors bind to PD-L1 on tumor cells, blocking the tumor immune escape pathway and maintaining T cell tumor-killing activity. PD-1 inhibitors are IgG4 antibodies with anti-inflammatory biological functions that target T cells. PD-1 is expressed on T cell surfaces, and PD-1 inhibitors bind to PD-1 on T cells to block the tumor immune escape pathway, preserving T cell tumor-killing activity. The TR-FRET PD1/PD-L1 assay kit can quantitatively detect PD1/PD-L1 binding activity, providing a technical tool for studying both inhibitors' mechanisms.

PD1 inhibitors are IgG4 antibodies, whose relatively unstable structure may reduce therapeutic efficacy. Therefore, nearly all PD1 inhibitors undergo S228P modification to enhance antibody stability. The S228P modification involves replacing serine 228 with proline in the IgG4 hinge region, reducing half-antibody exchange and improving structural integrity. Different PD1 inhibitors vary in modification levels, and imperfect modifications may lead to adverse effects. Antibody structure stability directly affects drug binding affinity and biological activity, making it a critical quality control parameter for PD1 inhibitors. TR-FRET technology can evaluate binding activity and compare PD1 inhibitors' interaction strength with PD-L1.

PD-L1 inhibitors are IgG1 antibodies, which have the biological function of recognizing pathogenic antigens and effectively identify PD-L1 expressed on tumor cell surfaces. Compared to IgG4 antibodies, IgG1 antibodies are structurally more stable and do not require additional modifications to maintain integrity. IgG1 antibodies also possess antibody-dependent cellular cytotoxicity (ADCC) effector functions, potentially enhancing PD-L1 inhibitors' antitumor activity. However, ADCC effects may also cause damage to normal tissues, requiring careful balancing in drug design. The TR-FRET PD1/PD-L1 assay kit can compare different PD-L1 inhibitors' binding affinity and evaluate their blocking efficiency.

Although PD1 and PD-L1 inhibitors act on the same signaling pathway, they target different molecules and cell types. PD1 inhibitors target PD1 molecules on T cell surfaces, affecting immune T cell function. By binding to PD1 on T cells, PD1 inhibitors prevent PD1/PD-L1 interaction, removing inhibitory signals for T cell activation. PD-L1 inhibitors target PD-L1 molecules on tumor cells, affecting tumor immune escape capabilities. By binding to PD-L1 on tumor cells, PD-L1 inhibitors block PD1/PD-L1 binding, exposing tumors to T cell recognition and attack. This target difference underlies their distinct mechanisms and clinical profiles. TR-FRET technology can study both inhibitors' blocking effects on PD1-PD-L1 interaction and evaluate functional activity.

PD1/PD-L1 binding is a critical step in immune checkpoint inhibition, and quantitative detection is essential for inhibitor research and quality control. TR-FRET technology offers homogeneous, wash-free, high-sensitivity, and high-throughput analysis of PD1/PD-L1 interaction. This technique uses donor-fluorophore-labeled PD1 protein and acceptor-fluorophore-labeled PD-L1 protein. When bound, fluorescence resonance energy transfer generates specific signals. Adding inhibitors reduces signal intensity, reflecting blocking efficacy. The TR-FRET PD1/PD-L1 assay kit can screen candidates blocking PD1-PD-L1 binding and evaluate half-maximal inhibitory concentration (IC50).

The TR-FRET PD1/PD-L1 assay kit has multifaceted applications in PD1/PD-L1 inhibitor research. For drug screening, it enables high-throughput screening of small molecules or antibodies blocking PD1-PD-L1 interaction, accelerating lead compound discovery. For activity evaluation, it quantitatively compares inhibitors' binding affinity and blocking efficiency, supporting structure optimization. For quality control, it assesses batch-to-batch consistency, ensuring drug stability and reliability. For mechanism studies, it evaluates PD1/PD-L1 interaction changes under various conditions, revealing detailed mechanisms. Compared to traditional ELISA, TR-FRET is simpler, faster, more sensitive, and better suited for high-throughput screening.

Nanjing UA-Bio Technology Co., Ltd. has independently developed the "UniOne® TR-FRET Human PD1/PD-L1 Binding Kit" (Catalog No.: UA086026), a high-performance analysis platform specifically designed for studying programmed death receptor 1 (PD-1) and its ligand PD-L1 interaction. Based on time-resolved fluorescence resonance energy transfer (TR-FRET) technology, this kit accurately and efficiently evaluates human PD-1/PD-L1 binding activity, providing standardized solutions for tumor immunotherapy, antibody drug development, and immune checkpoint inhibitor screening.

Nanjing UA-Bio Technology specializes in providing cutting-edge reagents and tools for immunology, cell therapy, and innovative drug development. For details about the "UniOne® TR-FRET Human PD1/PD-L1 Binding Kit" (Catalog No.: UA086026), including specifications, validation data, or application inquiries, please contact us.